As long as current rebating and contracting practices continue, payers are part of the problem, not the solution, in promoting development of a vibrant biosimilars market, US FDA Commissioner Scott Gottlieb told America's Health Insurance Plans at their National Health Policy Conference in Washington, D.C. March 7.
In a speech on "Affording Tomorrow's Cures," Gottlieb steered clear of challenging high drug pricing and instead leveled strong criticism at the complicated system of rebating and contracting employed by...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?